BREAKING NEWS: Novartis Buys Tourmaline Bio, Setting Up Showdown With Novo Nordisk

Novartis is acquiring Tourmaline Bio for $1.4B to gain pacibekitug, a promising IL-6 inhibitor for cardiovascular disease, setting up a direct rivalry with Novo Nordisk's ziltivekimab.

via: https://insights.citeline.com//scrip/business/deals/breaking-news-novartis-buys-tourmaline-bio-setting-up-showdown-with-novo-nordisk-KCLTLWYZRNBZJGPVNSDLWKE7SQ/